Head/Neck Cancer

Top Story

Fewer newly diagnosed patients with cancer lack insurance after ACA

Fewer newly diagnosed patients with cancer lack insurance after ACA
October 19, 2017

Uninsurance rates among patients newly diagnosed with cancer dropped one-third during the Affordable Care Act’s first year of implementation, according to study results.

Since implementation of the ACA in 2014, the number of uninsured individuals has reached a historical low.

Meeting News

Esophageal cancer in first-degree relative increases Barrett’s risk

October 18, 2017
ORLANDO — Patients with Barrett’s esophagus who have a first-degree relative with esophageal adenocarcinoma are at 5.5-fold increased risk for progression to…
In the Journals Plus

Malignant thyroid nodules grow faster than benign nodules

October 18, 2017
Malignant thyroid nodules are more likely to grow at least 2 mm per year and increase in volume compared with benign thyroid nodules, according to findings published in…

AACR: Advances in cancer research, medical funding allow for ‘phenomenal’ progress

October 17, 2017
Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized…
More Headlines »
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Video
Meeting News

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

Support for this activity has been provided through educational grants from Amgen; Celgene Corporation; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging…
More »
Advertisement
Advertisement